Trastuzumab deruxtecan (T-Dxd) is the second HER2-directed antibody–drug conjugate (ADC) approved by the FDA for HER2-positive metastatic breast cancer and the first agent directed towards HER2 for inoperable or metastatic low HER2 breast cancer [27]. The gene discussed is ERBB2; the disease is breast carcinoma.